Last reviewed · How we verify
NCT05181488
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
NA trial testing intraoperative radiotherapy, IORT in Resectable Pancreatic Cancer in 80 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2026
Quick facts
| Lead sponsor | Yona Cho |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 2 April 2020 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- intraoperative radiotherapy, IORT
Conditions studied
- Resectable Pancreatic Cancer — all drugs for Resectable Pancreatic Cancer →
Sponsor
Yona Cho
Who can join
20 and older, any sex, with Resectable Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05181488
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Resectable Pancreatic Cancer
Currently open trials in the same condition.
- NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
- NCT06978322 — Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Canc · recruiting
- NCT05624918 — A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT05209074 — Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma · Phase 1 · active not recruiting
- NCT03138720 — Pre-operative Treatment for Patients With Untreated Pancreatic Cancer · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05181488 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yona Cho
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05181488.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing